Articles related to GLP-1 RECEPTOR AGONISTS

Among 39 adults who had stopped GLP-1 therapy after substantial weight loss, medically tailored meals and app-based behavioral support were associated with less four-month weight regain than usual care in a small pilot trial.

A 67-year-old man with obesity and obesity-related liver disease underwent endoscopic sleeve gastroplasty after previous weight-loss approaches, including GLP-1 therapy, provided insufficient durability, ultimately reporting a weight loss exceeding 80 lb.

A review identified 15 reports of Wernicke encephalopathy among patients receiving GLP-1 therapies, most accompanied by poor intake, vomiting, weight loss, or malnutrition, highlighting a rare safety signal without establishing drug-related causality.

Mayim Bialik reports prolonged gastrointestinal symptoms after one dose of an unnamed GLP-1 medication taken for autoimmune symptoms. Her account describes individual intolerance, not the frequency of severe reactions or evidence of autoimmune benefit.

In a large multinational target-trial emulation, adults with serious mental illness who initiated GLP-1 receptor agonists experienced lower mortality and cardiovascular event rates than matched patients initiating SGLT2 inhibitors, though residual confounding remains a key limitation.

Nearly one in six pediatric GLP-1 receptor agonist users received a nutritional-deficiency or related diagnosis within one year, while nutrition counseling remained limited and generally occurred months after treatment initiation.